Search This Blog

Thursday, November 1, 2018

AMAG Pharma Q3 top line down 2%; non-GAAP EBITDA down 34%


AMAG Pharmaceuticals (AMAG -15.5%) slumps on more than double normal volume after releasing Q3 results this morning that included a 1.7% drop in revenue. Highlights:
Revenues: $122.2M, down 1.7% due to supply constraints from third-party supplier of intramuscular injection products and by the entry of a generic competitor.
Makena sales down 17.8% to $80.2M. Faraheme/MuGard sales up 41.1% to $37.1M.
Net income: $30.8M (+120.2%); EPS: $0.89 (+120.6%); cash flow ops (9 mo.): $84.9M (-2.0%).
Non-GAAP EBITDA: $30.0M (-33.5%).
2018 guidance: Non-GAAP EBITDA: $115M – 125M from $95M – 115M.
Previously: AMAG Pharmaceuticals EPS of -$1.88 (Nov. 1)

Ensign Group Acquires Texas, Kansas, Idaho Senior Housing Communities


The Ensign Group, Inc. (ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care and assisted living companies, announced today that Bridgestone Living LLC, Ensign’s assisted and independent living portfolio company, acquired the operations of four assisted living and memory care communities in Texas subject to a long-term lease. The acquisition was effective November 1, 2018, and includes the following communities:
  • Canyon Creek Memory Care, a 52-unit memory care facility located in Temple, Texas;
  • Bridgewater Memory Care, a 52-unit memory care facility located in Granbury, Texas;
  • Lakeshore Assisted Living and Memory Care, a 46-unit assisted living and 30-unit memory care community located in Rockwall, Texas; and
  • Windsor Court Senior Living, a retirement community with 36 independent living units, 16 memory care units, and seven assisted living units located in Weatherford, Texas.
“We continue to see many opportunities for growth in the Dallas-Fort Worth metro area and are confident these four communities will be great additions to our existing operations there,” said Christopher Christensen, Ensign’s President and Chief Executive Officer, noting that this is Ensign’s third acquisition in the area in 2018, joining the two assisted living facilities and the post-acute care retirement community acquired earlier this year in separate transactions.  “As is the case with all of our acquisition efforts, we pursued these operations because our local leaders see a pathway to meaningfully impact the quality of the healthcare services delivered to their residents and resulting occupancy improvements.” He added that these four communities had an average occupancy rate of approximately 84% at the time of acquisition.
In separate transactions on the same day, Ensign announced that it acquired through portfolio subsidiaries the real estate and operations of Rock Creek of Ottawa, a post-acute care retirement campus in Kansas, as well as the real estate and operations of two skilled nursing facilities in Idaho. The Kansas and Idaho acquisitions were also effective November 1, 2018.
This acquisition, along with its other acquisitions announced today, brings Ensign’s growing portfolio to 188 skilled nursing operations, 24 of which also include assisted living operations, 56 assisted and independent living operations, 21 hospice agencies, 22 home health agencies and six home care businesses across sixteen states.  Ensign owns the real estate at 72 of its 244 healthcare operations.  Mr. Christensen reaffirmed that the organization is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, assisted living and other healthcare related businesses throughout the United States.

Gritstone started at buy by Cowen


Cowen assumed coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating on the stock.

Fitbit stock heads toward record gain after surprise profit


Shares of Fitbit Inc. are on track to post their biggest single-day percentage gain in the company’s history after the wearables pioneer posted a surprise profit for the third quarter.
Fitbit FIT, +25.48%  generated adjusted earnings per share of 4 cents, while analysts surveyed by FactSet had been projecting a 1 cent per-share loss. Fitbit had not claimed a quarterly profit in more than two years. The company’s revenue of $393.6 million exceeded the $381.3 million FactSet consensus.
“The quarter represented meaningful incremental progress toward the company’s goals of achieving greater financial stability and transforming the business beyond fitness trackers with a greater emphasis on measurable health outcomes,” wrote William Blair analyst Jeffrey Garro, who rates the stock at market perform.
Fitbit shares are up nearly 24% in Thursday morning trading. The stock would have to close up more than 15.2% percent to set a new record for its largest single-day gain.
William Blair’s Garro was encouraged by the company’s commentary around the new Charge 3 fitness tracker, which was introduced during the quarter.

“Initial sell-in contributed meaningfully to third quarter results by our estimate,” he wrote. “Management commented that sell-through has been strong, indicating further momentum for the fourth quarter and noted that direct-to-consumer pre-orders through Fitbit.com will positively impact the fourth quarter.”
Oppenheimer analyst Andrew Uerkwitz wrote that Fitbit’s transition to becoming a more services-oriented business has “been a slog,” but he’s upbeat about both this area of Fitbit’s business as well as its device opportunities.
“With trackers finding a base and smartwatches gaining traction (internally now 49% of revs and 2nd in global market share), the hardware business seems to have found its footing and we could see growth in 2019,” he wrote. “More important, as digital health becomes material, investors should expect more detail on monetization and user strategy.”
Uerkwitz has an outperform rating and $8 target on the shares.

Not all are convinced about the company’s turnaround, however. Morgan Stanley’s Yuuji Anderson wrote that the holiday quarter “is when the rubber meets the road.” He cautions that the company’s recent revenue beats could be the result of the way it timed new product introductions. “We look towards holiday sell-through and inventory levels exiting the year as more representative of Fitbit’s demand trends,” he said.
Anderson is skeptical that Fitbit’s devices will perform strongly during the holidays. The company forecast better earnings for the fourth quarter than analysts expected, but the revenue guidance was below consensus estimates.
“We think the current pace of new features is not enough to stabilize declining demand this year and are concerned that the functional similarities between Charge 3 and Versa will result in cannibalization,” he said. Anderson rates the stock at underweight with a price target of $4.

Fitbit’s 24% rally on Thursday has cost short sellers $57 million in mark-to-market losses, according to S3 Partners, a financial technology and analytics firm. The price movement has wiped out the $55 million in year-to-date profits that short sellers had racked up during the rest of 2018.
Ihor Dusaniwsky, the managing director of predictive analytics at S3, said that the stock rally on Thursday isn’t the result of short covering, as short sellers are adding to positions as the shares gain.
Fitbit shares have gained 3.1% so far this year, while the S&P 500 SPX, +0.81% has risen 2.2%.

Constellation Pharmaceuticals receives fast track tag for myelofibrosis med


Constellation Pharmaceuticals announced that it has received Fast Track designation from the FDA for CPI-0610 in treatment of myelofibrosis based on preliminary results from the Company’s Phase 2 study, MANIFEST. Constellation is developing CPI-0610 with the goal of providing a new treatment option for patients with MF who have experienced disease progression after treatment with Jakafi, the only approved therapy for MF. Enrollment is ongoing in the Phase 2 portion of the open-label Phase 1/2 MANIFEST clinical trial, which is exploring CPI-0610’s potential both as a monotherapy and as a combination therapy with Jakafi. As previously reported, preliminary data demonstrated clinical activity, such as spleen volume reduction, symptom improvement, increase in hemoglobin levels, and conversion to transfusion independent status in a patient who was transfusion dependent. Constellation recently expanded the MANIFEST study to include a third cohort, designed to evaluate CPI-0610 as a first-line therapy in combination with ruxolitinib in JAK 1/2-inhibitor-naive MF patients.
https://thefly.com/landingPageNews.php?id=2815227

Aptinyx completes enrollment in Phase 2 diabetic neuropathy study


Aptinyx announced enrollment completion for the company’s Phase 2 study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy. NYX-2925 is a novel modulator of NMDA receptors and its development for painful DPN has been granted Fast Track designation by the U.S. Food and Drug Administration. The company expects to announce top-line data from the study early in the first quarter of 2019. The study is a randomized, double-blind, placebo-controlled study in which subjects receive oral, once-daily dosing of either placebo or NYX-2925 for four weeks. The primary endpoint of the study is the change in subjects’ average daily pain scores on the Numerical Rating Scale between the baseline period and the fourth week of treatment. Multiple dose levels of NYX-2925 are under evaluation in the study. Secondary endpoints include the effect of NYX-2925 on pain characteristics, sleep interference, and psychological state, as well as further assessment of safety and tolerability. The company is conducting the study across 35 sites in the U.S. and has achieved the targeted enrollment of 300 subjects.
https://thefly.com/landingPageNews.php?id=2815271

Morgan Stanley ups Anthem price target to $372 after ‘bullish’ 2019 comments


Morgan Stanley analyst Zack Sopcak said that Anthem management commented a number of times on the company’s Q3 earnings call that 2019 consensus EPS, which had been $17.13, was “light.” Assuming a low end of 8% growth and high end of 12% growth would make the range $17.30-$17.90, he noted. The company’s Q3 results also showed continued strong operating performance and its 2018 guidance was raised by more than the Q3 beat, noted Sopcak. Given the Q3 performance and “bullish” 2019 commentary, Sopcak raised his price target Anthem shares to $372 from $368 and keeps an Overweight rating on the stock.
https://thefly.com/landingPageNews.php?id=2815277